Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies.

Literature DB >> 3122267

Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies.

H R Maxon¹, E A Deutsch, S R Thomas, K Libson, S J Lukes, C C Williams, S Ali.

Abstract

Investigation of the biodistribution of subtherapeutic amounts of a new, chromatographically purified rhenium-186(tin) hydroxyethylidene diphosphonate radiopharmaceutical have been completed in five patients with metastatic carcinoma to bone. The new agent localizes in metastatic foci in bone in the same manner as do standard technetium-99m diphosphonate bone-scanning agents and appears able to deliver therapeutic radiation doses of thousands of rads (tens of grays) to these metastatic foci while limiting the total red marrow dose to less than 75 rad (0.75 Gy). The simultaneous treatment of multiple metastatic foci in bone appears feasible with this new agent.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1988 PMID： 3122267 DOI： 10.1148/radiology.166.2.3122267

Source DB: PubMed Journal: Radiology ISSN： 0033-8419 Impact factor: 11.105

Keyword Cloud
Cited

16 in total

Review 1. Radiopharmaceuticals: state of the art.

Authors: A M Verbruggen
Journal: Eur J Nucl Med Date: 1990

2. Treatment of bone metastases.

Authors: R F Carretta
Journal: West J Med Date: 1990-06

3. Radionuclide Therapy of Bone Metastases.

Authors: Manfred Fischer; Willm U Kampen
Journal: Breast Care (Basel) Date: 2012-04-24 Impact factor: 2.860

4. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Authors: W Y Lin; C P Lin; S J Yeh; B T Hsieh; Z T Tsai; G Ting; T C Yen; S J Wang; F F Knapp; M G Stabin
Journal: Eur J Nucl Med Date: 1997-06

Review 9. Radionuclide therapy revisited.

Authors: C A Hoefnagel
Journal: Eur J Nucl Med Date: 1991

10. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.

Authors: J M de Klerk; B A Zonnenberg; A D van het Schip; A van Dijk; S H Han; J M Quirijnen; G H Blijham; P P van Rijk
Journal: Eur J Nucl Med Date: 1994-10

Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies.

Review 1. Radiopharmaceuticals: state of the art.

2. Treatment of bone metastases.

3. Radionuclide Therapy of Bone Metastases.

4. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Review 5. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

6. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Review 7. The management of painful bone metastases with an emphasis on radionuclide therapy.

8. [Pain palliation using unsealed radionuclides].

Review 9. Radionuclide therapy revisited.

10. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.